MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
May 21 closing price
Price
$27.46
Change
-$0.54 (-1.93%)
Net Assets
52.17M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
May 21, 2025

HRTS sees its Stochastic Oscillator recovers from oversold territory

On May 19, 2025, the Stochastic Oscillator for HRTS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 18 instances where the indicator left the oversold zone. In of the 18 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HRTS just turned positive on May 20, 2025. Looking at past instances where HRTS's MACD turned positive, the stock continued to rise in of 16 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 92 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 51 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 21, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTS as a result. In of 19 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

HRTS moved below its 50-day moving average on May 01, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Amgen (NASDAQ:AMGN), Medtronic plc (NYSE:MDT), Bristol-Myers Squibb Co (NYSE:BMY), Boston Scientific Corp (NYSE:BSX).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Obesity & Cardiometabolic ETF ETF is 79.99B. The market cap for tickers in the group ranges from 3.51M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Obesity & Cardiometabolic ETF ETF was 3%. For the same ETF, the average monthly price growth was 0%, and the average quarterly price growth was -12%. AKRO experienced the highest price growth at 28%, while CRNX experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Tema Obesity & Cardiometabolic ETF ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was 26% and the average quarterly volume growth was 50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 77
Price Growth Rating: 51
SMR Rating: 100
Profit Risk Rating: 72
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co